Skip to content
Search

Latest Stories

DHSC updates June 2023 price concessions after CPE members report medicine pricing issues

Department of Health and Social Care (DHSC) has updated the final price concessions for June 2023, following a discussion by Community Pharmacy England regarding medicine pricing issues reported by pharmacy owners (its members).

A price concession only applies for the month it is granted; any prices agreed for concessions requested late in the month will roll over into the following month.


Community Pharmacy England encouraged pharmacies to report any problems obtaining a Part VIII product at or below the stated Drug Tariff price, using the online feedback form on the Community Pharmacy England website along with full details of the supplier and price paid for any products sourced above the Drug Tariff price.

The association will investigate the extent of the problem and, if appropriate, discuss the issue with DHSC.

“Since this announcement, we have sent a strong and clear message back to Government that pharmacies cannot continue to subsidise the NHS medicines bill. Following the review of the concessionary price process, a package of measures has been developed to improve the system,” said CPE.

One of the solutions agreed between CPE and DHSC is that from 1st April 2023, all products granted a concessionary price will be classified as ‘Discount Not Deducted’ for the month(s) in which they are on concession.

Furthermore, from May 2023, DHSC has implemented a process to roll over prices to the following month for any concessions requested after the 23rd of the month provided these prices were agreed with us.

CPE is also continuing to work with DHSC on how a ‘retrospective increased payment’ my apply, when appropriate.

Full list below:

DrugPack sizePrice concession
* Alginate raft-forming oral suspension sugar free500£3.80
Amiloride 5mg tablets28£13.46
Amoxicillin 125mg/5ml oral suspension sugar free100£2.68
Benzoyl peroxide 5% / Clindamycin 1% gel60£22.22
Buprenorphine 8mg sublingual tablets sugar free7£11.36
Calamine lotion200£1.86
Chloramphenicol 0.5% eye drops10£12.51
Chlorphenamine 2mg/5ml oral solution sugar free150£4.01
Clotrimazole 500mg pessary and Clotrimazole 2% cream1£10.79
Co-careldopa 12.5mg/50mg tablets90£4.93
Co-trimoxazole 80mg/400mg tablets28£2.34
Docusate 50mg/5ml oral solution sugar free300£18.81
Flucloxacillin 250mg capsules28£2.45
Isoniazid 100mg tablets28£60.00
Ivabradine 5mg tablets56£28.33
Letrozole 2.5mg tablets14£6.66
Methylphenidate 5mg tablets30£3.45
Mometasone 0.1% cream30£3.60
Mycophenolate mofetil 500mg tablets50£7.69
Pantoprazole 20mg gastro-resistant tablets28£6.62
Pantoprazole 40mg gastro-resistant tablets28£9.23
Paracetamol 500mg effervescent tablets100£10.34
Pregabalin 300mg capsules56£4.02
Promethazine hydrochloride 25mg tablets56£29.32
Quinine sulfate 200mg tablets28£7.97
Risperidone 500microgram tablets20£2.98
Rosuvastatin 20mg tablets28£4.98
Sodium chloride 0.9% nebuliser liquid 2.5ml unit dose ampoules20£11.04
Tacrolimus 0.1% ointment60£41.69
Tacrolimus 0.1% ointment30£22.36
Tamsulosin 400microgram / Dutasteride 500microgram capsules30£14.53
Tolterodine 2mg tablets56£3.55
Topiramate 100mg tablets60£16.53
Tramadol 37.5mg / Paracetamol 325mg tablets60£7.38
Trazodone 50mg capsules84£3.45
Venlafaxine 75mg tablets56£11.51
Zolmitriptan 2.5mg tablets6£18.85
Zolmitriptan 2.5mg tablets12£37.70

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less